The conditional expression of activated HER2/neu gene under its endogenous promoter in the mammary epithelium of the mouse results in accelerated lobular development and focal mammary tumors. Carcinogenesis, however, requires ampli®cation and considerably increased expression levels of oncogenic neu. Deducing from the multiple genetic aberrations required for human breast cancer to develop, we hypothesized that in addition to the over-expression of an activated HER2/ neu, secondary aberrations would occur. We have therefore conducted a genomic screen for chromosomal imbalances and translocations using comparative genomic hybridization and spectral karyotyping. The results reveal a moderate degree of chromosomal instability and micronuclei formation in short-term cultures established from primary tumors. Genomic instability appears to be linked to the ampli®cation of functional centrosomes, a phenomenon that we frequently observed in other tumor types. Seventy per cent of the tumors revealed genomic ampli®cation of HER2/neu, often in the form of double minute chromosomes, which correlated with recurring loss of mouse chromosome 4D-E, a region that is orthologous to distal human chromosome 1p. It is likely that this region contains putative tumor suppressor genes whose inactivation is required for tumor formation in this model of human breast cancer.
Introduction
Modeling human cancer in the mouse has become an increasingly valuable tool for understanding the genetic events responsible for tumor initiation and progression. Murine models can be used to monitor the eects of tissue speci®c elimination of tumor suppressor gene function and of the over-expression of cellular oncogenes. Numerous models for human breast cancer have been described (Hennighausen, 2000) , many of which attempt to recapitulate the genetics of human breast cancer by over-expressing oncogenes known to be involved in the human disease. For instance, the forced expression of c-myc, HER2/neu, and cyclinD1, respectively, under the control of the mammary gland speci®c MMTV-promoter results in mammary gland adenocarcinomas (Muller et al., 1988; Stewart et al., 1984; Wang et al., 1994) . Accordingly, the conditional, tissue speci®c depletion of BRCA1 function results in tumor formation (Xu et al., 1999a,b) and the impairment of p53 and RB1 function via expression of SV40 large T antigen under the control of the C3 promoter induces K-ras ampli®cation and tumorigenesis (Liu et al., 1998) . As in human cancers, it is likely that tumorigenesis in the mouse is promoted, or at least accompanied by, the acquisition of non-random chromosomal aneuploidies. For instance, human breast cancers frequently exhibit extra copies of chromosome 20, gains of chromosome arms 1q, 8q, and 17q, and losses that map to 8p and 17p (Ried et al., 1995; Tirkkonen et al., 1998) . It would be intriguing to query whether this particular distribution of genomic imbalances is maintained in murine models of breast cancer despite the considerable shuing of chromosomes during the course of evolution. Such comparative cytogenetic analyses, however, have been hampered by the intricacy of reliably karyotyping mouse chromosomes. We have therefore used spectral karyotyping (SKY) (Liyanage et al., 1996; SchroÈ ck et al., 1996b) and comparative genomic hybridization (CGH) (Kallioniemi et al., 1992; Weaver et al., 1999) , two techniques that overcome these hurdles, to characterize chromosomal aberrations in a mouse model of human breast cancer induced by the expression of an activated mutated HER2/neu under its endogenous promoter (Andrechek et al., 2000) . As part of the family of epithelial growth factor receptors, the HER2/neu oncogene is ampli®ed in about 25% of human breast cancers (Revillion et al., 1998) . Genomic ampli®cations of the oncogenes HER2/neu and c-myc and potential deletions of the tumor suppressor genes p53 and BRCA1 were assessed using¯uorescence in situ hybridization. As a potential basis for the observed chromosomal aneuploidy we investigated centrosome integrity in these mammary cells using immunohistochemical visualization of g-tubulin. We consider that such studies provide important baselines for the molecular analysis of murine tumors and contribute to the validation of mouse models for speci®c human cancers.
Results
The over-expression of an activated HER2/neu oncogene regulated via its physiological promoter results in the development of mammary gland adenocarcinomas in transgenic mice (Andrechek et al., 2000) . Despite the fact that karyotype information could contribute to the validation of tumor models and provide entry points for the molecular cloning of cancer associated genes, data on chromosomal aberrations in murine carcinoma models remain sketchy.
In this study, we have applied molecular cytogenetic techniques, including SKY, CGH, and FISH with gene speci®c BAC clones to establish a comparative map of chromosomal aberrations in a series of 12 primary tumors induced by the expression of a constitutively activated HER2/neu. Karyotype analysis was performed on short-term cultures derived from primary tumors using SKY. An example of a SKY analysis is shown in Figure 1 for tumor #22. The most frequent chromosomal aberration was a deletion or monosomy of chromosome 4 (7 of 12 tumors). Except for the deleted chromosome 4, we could not detect recurring structural chromosomal aberrations, however, clonal numerical aberrations (chromosomal aneuploidies) were common. One tumor, #21, was normal both by SKY and CGH analysis. We cannot exclude that this is due to the preferential culture of ®broblasts or normal breast epithelial cells. With the exception of two tumors, in which we observed a diploid and tetraploid (#22) and triploid stem line (#19), the cells were predominantly diploid. Karyotypes for all of the tumors are summarized in Table 1 and can be retrieved from the SKY database at In order to de®ne the deleted region of chromosome 4 with higher resolution, we used FISH with genetically mapped BAC clones to determine the smallest deleted interval. The hybridization patterns for tumor #22 are shown in Figure 2a ± c. The results indicate BAC clones that map to 53.6 cM (D4Mit149) and 76.5 cM (D4Mit254) as well as a BAC clones for the tumor suppressor gene p16 (139P5 at 42.7 cM) are deleted on one allele, however, clone D4Mit229 (20.6 cM) is retained. The breakpoint is therefore proximal to 42.7 cM on the genetic map, which corresponds to chromosome band 4C3. This region of mouse chromosome 4, which was deleted in all but one tumor with chromosome 4 aberrations, is orthologous to human chromosome 1p32-1p36 and 9p.
Forty-eight per cent of the metaphases from 10 tumors analysed showed chromosomes that had acquired loss of the heterochromatic regions close to the centromere on band A1 (Figure 1 ). The chromosomes most commonly aected by the loss of the paracentromeric heterochromatic regionswere chromosomes 8 (®ve of 12 tumors), chromosome 9 (seven of 12 tumors), and less frequently chromosome 14 (two of 12 tumors), chromosome 7, 18 and X (one of 12 tumors, see also Table 1 ).
The analysis of human carcinomas using SKY and CGH has revealed that the majority of chromosomal aberrations result in genomic imbalances (Ghadimi et al., 1999) , and that recurring copy number changes of particular chromosomes or chromosomal regions are a de®ning parameter of distinct human cancers . In order to establish comparative maps of genomic imbalances, the series of 12 murine mammary gland adenocarcinomas was analysed by CGH. The results are summarized in Figure 3 (see also the website http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi for the CGH and SKY results). CGH con®rmed the frequent loss of distal chromosome 4 as identi®ed by SKY. High-level copy number increases that mapped to distal chromosome 11 were observed in six of 12 tumors, and low copy number increases in the same region were found in two additional tumors. In two cases (#20, #22) extra copies of chromosome 15 were detected. Both the c-myc oncogene and telomerase reverse transcriptase gene (hTRT) map to this chromosome. Less frequent copy number changes were observed on chromosome 2 (gained in #20/2 and #15) and 19 (gained in #5 and #22) and losses of the distal portion of chromosome 9 (#15, #18, #20). In total, we observed 34 copy number changes: divided by the number of cases, this translates to an average number of copy alterations (ANCA) of 2.8.
Eight of 12 tumors revealed metaphases containing extra-chromosomal DNA fragments whose shape was consistent with double minute chromosomes (DMs). The number of DMs ranged from 50 to 100 per cell (Figure 4b ,c). DMs in solid tumors are frequently the cytogenetic correlate of oncogene ampli®cation (Alitalo et al., 1985) . Since the amplicon identi®ed by CGH mapped to the distal end of chromosome 11, we hypothesized that the HER2/neu gene, which maps to mouse chromosome 11 at 57 cM was the target for this gene ampli®cation. FISH with a BAC clone speci®c for HER2/neu con®rmed our hypothesis. Seven tumors contained greatly increased copy numbers of this oncogene located on the DMs (Figure 4b ,c, Table 2 ). The genomic ampli®cation detected by CGH is consistent with previous results using Southern-blot analysis with the exception of case #20, where CGH and FISH revealed greatly increased copy numbers for HER2/neu, however, ampli®cation was not detected by Southern-blot analysis.
Genomic deletions frequently contribute to allelic loss and tumor suppressor gene inactivation in human cancers. We therefore investigated whether loss of the tumor suppressor genes p53 and brcal, both involved in human breast cancers, were required for tumorigenesis in this mouse model. FISH analysis with a BAC clone for brcal clearly demonstrated that this tumor suppressor gene, which also maps to the distal end of chromosome 11 (SchroÈ ck et al., 1996a) , was excluded from the amplicon and was present in two copies in diploid cells. We could also show that inactivation of p53 (at least via chromosomal deletion) was not necessary for tumorigenesis because two copies were consistently observed in the diploid cells. The c-myc oncogene was not present in copy numbers higher than the ploidy of mouse chromosome 15. Examples of the FISH experiments are provided in Figure 4 and the results compiled in Table 2 .
With one exception, all tumors revealed predominantly numerical chromosomal aberrations (Table 1) . Such aberrations can be due to compromised chromosome segregation ®delity during mitotic cell division. The centrosome organizes the spindle apparatus prior to cell division and nucleates the proper assembly of microtubules whose attachment to the kinetochore at each chromosome is essential for correct segregation (Kellogg et al., 1994) . We have previously shown that centrosome abnormalities occur exclusively in human colorectal carcinomas that are aneuploid, but not in their diploid, mismatch repair de®cient counterparts (Ghadimi et al., 2000) . We therefore wanted to investigate whether abnormalities and ampli®cation of functional centrosomes could, at least partially, contribute to the observed chromosomal aneuploidy. The centrosome can be visualized using an antibody against g-tubulin, a protein that is concentrated in the centrosome during all stages of the cell cycle. The (Figure 5a ) we observed dierent patterns of centrosome abnormalities. In many instances, the centrosomes lined up similar to pearls on a string at the edge of the nucleus ( Figure  5b) . A second pattern displayed centrosomes located in the periphery of the cells and obviously detached from the nucleus (Figure 5c ). The third pattern indicated centrosome replication in the absence of centrosome separation because clusters of centrosomes were observed near the nucleus (Figure 5d ). Dual immunouorescence using antibodies against a-and g-tubulin was performed to assess whether supernumerary centrosomes were able to nucleate tubulin, form mitotic spindles and cause multipolar mitoses. The results shown in Figure 6 clearly demonstrate ampli®cation of functional centrosomes. Evaluation of the nuclear DNA counterstain also showed the frequent occurrence of micronuclei. Micronuclei are indicative of chromosome breakage, increased formation of dicentric chromosomes, and lagging chromosomes due to errors in cell cycle timing (MuÈ ller et al., 1996) . Twenty-®ve per cent of the cells were accompanied by micronuclei (as determined by propidium iodide Column 2 indicates the per cent of cells containing double minute chromosomes for each sample. Columns 3, 4 and 5 show the results of FISH experiments with the BAC clones for the p53 and BRCA1 tumor suppressor genes and for the c-myc oncogene, respectively. Column 6 displays the enumeration of centrosome numbers using an antibody against g-tubulin. nd, not determined staining), and approximately 60% revealed aberrant centrosome numbers. Micronuclei occurred only rarely in cells with normal centrosome numbers (7%) but were frequently found in cells with additional centrosomes (18%). However, we observed a signi®cant number of cells with centrosome abnormalities in the absence of micronucleus formation (45% of all cells analysed).
Discussion
The acquisition of tumor speci®c patterns of chromosomal imbalances is a de®ning characteristic of cancers of epithelial origin. For instance, colorectal carcinomas almost invariably reveal copy number increases of chromosomes 7 and 13, and of chromosome arms 8q and 20q, while chromosome 18 is frequently lost (Ried et al., 1996) . Also, the emergence of these chromosomal aneuploidies occurs in a more or less de®ned sequence of events. Trisomy of chromosome 7 is the earliest events that can already be observed in small polyps (Heim and Mitelman, 1995) . Such a linear progression is less well established during breast carcinogenesis, however, it is clear that mammary tumors display a non-random involvement of certain chromosomes. Cytogenetic and molecular cytogenetic analyses have clearly shown that a gain of chromosome arm 1q, as well as gains of chromosome arms 8q and 17q accompanied by losses of the respective short arms, are recurrently found in breast cancers (Heim and Mitelman, 1995) . It is even possible to assign certain cytogenetic features to subgroups of breast cancers, that dier with respect to the nuclear DNA content, tumor size, lymph node status, and clinical course (Isola et al., 1995; Ried et al., 1995; Tirkkonen et al., 1998) . Therefore, it appears that the acquisition and maintenance of a distinct pattern of genomic imbalances is a feature that is strongly selected for and maintained despite intra-tumor heterogeneity and chromosome instability. With this information in mind it is intriguing to determine (i) whether mouse models of dierent carcinomas share this characteristic pattern of chromosomal aneuploidy, and (ii) whether this pattern is dependent upon the mode of tumor induction. We have previously reported the molecular cytogenetic evaluation of mouse mammary gland adenocarcinomas induced by over-expression of the c-myc oncogene under the control of the MMTV-promoter (Weaver et al., 1999) . Here we extend such comparative molecular cancer cytogenetics to the evaluation of tumors induced by the conditional expression of an activated HER2/neu gene under the transcriptional control of its endogenous promoter (Andrechek et al., 2000) . During the course of mammalian chromosome evolution, human and mouse chromosomes have experienced a signi®cant degree of reorganization (O'Brien et al., 1999) . Comparison of chromosome aberration maps could therefore, with increased resolution, pinpoint genes whose involvement in tumorigenesis is required across species boundaries. Such a comparison would be particularly interesting for chromosomes that are found in a speci®c aberration pattern in human cancers, for instance as an isochromosome. Human chromosome 17 serves as such an example: sequences on chromosome arm 17p are frequently lost (with p53 as the target), while chromosome 17q is often gained (including HER2/neu and as yet to be identi®ed second oncogene on human chromosome 17q23), occasionally via isochromosome 17q formation. Since HER2/neu and p53 both reside on the same arm of mouse chromosome 11 chromosome translocations or interstitial deletions would have to occur if deletions of p53 and maintenance of HER2/neu are both required for tumorigenesis. Our molecular cytogenetic evaluation has shown that the tumors in this model system do not require the acquisition of the equivalent of an isochromosome 17q in human breast cancers. While the genomic ampli®-cation of HER2/neu is required for tumorigenesis, as illustrated by the presence of DMs, deletions of p53 are not present. CGH analysis clearly con®rmed the genomic ampli®cation of mouse chromosome 11C-D, the mapping position of the oncogene HER2/neu (11D). Of note, the same percentage of tumors revealed loss of distal mouse chromosome 4. The acquisition of HER2/neu ampli®cation appeared to be linked to chromosome 4 deletions; only one tumor showed a gain of 11D that was not accompanied by the loss of parts or the entire homologue of chromosome 4. We had previously observed deletions of mouse chromosome 4 in MMTV-c-myc induced mammary gland adenocarcinomas (Weaver et al., 1999) and in conditional knockouts for the tumor suppressor gene BRCA1 (Weaver et al., submitted) . These data therefore strongly suggest that a yet unidenti®ed tumor suppressor gene resides at this chromosomal locus. This result is even more signi®cant because distal mouse chromosome 4 is orthologous to human chromosome 1p. Human chromosome 1p has been shown in several reports to be subject to copy number loss in human breast cancers (Bieche et al., 1994) . One potential candidate gene is p73, a member of the p53 gene family (Chen et al., 2001) . Interestingly, in human neuroblastomas, genomic loss of chromosome 1p is associated with ampli®cation of the n-myc oncogene, frequently in (Bieche et al., 1994) . One could hypothesize that the common and coordinate loss of chromosome band 4D and the emergence of DMs indicates that the function of a tumor suppressor gene in this region might extend to the suppression of gene ampli®cation. The homology of distal mouse chromosome 4 also comprises region 9p21 in humans, which is the site of the p16INK4A and p19INK4d genes. These genes are involved in cellular senescence and immortalization and are therefore additional potential tumor suppressor candidate genes (Carnero et al., 2000) .
Our data also suggest that neither copy number increases of the c-myc oncogene, nor deletions of the tumor suppressor genes p53 or BRCA1, were required for tumorigenesis in this model. We can, however, not exclude the possibility of functional inactivation of either of these tumor suppressor genes by mechanisms dierent from chromosomal deletions. This is in contrast to tumors in conditional knockout mutants for BRCA1, in which both cytogenetic and Western-blot analyses suggest the frequent inactivation of p53 (Weaver et al., submitted) .
CGH analyses of human carcinomas have provided evidence that tumor staging and tumor aggressiveness correlate with the degree of genomic instability as measured by the average number of chromosomal aberrations (ANCA). For instance, diploid breast carcinomas display an ANCA index of 2.4 ± 5, whereas aneuploid carcinomas, whose prognosis is much worse, show an ANCA of 6.8 ± 12 . The ANCA index in the mouse models of human breast cancer that we have studied so far is in general similar to that observed in human carcinomas. In mammary gland adenocarcinomas induced by c-myc over-expression, the ANCA is 5.75, and in BRCA1-de®cient aneuploid tumors 8.0. In the HER2/neu model only relatively few chromosomal aberrations were detected (ANCA=2.8). It also appears that those tumor models that were induced by a strong oncogenic stimulus show fewer copy alterations than those induced by the tissue speci®c deletion of tumor suppressor genes. The lower ANCA value occurs even in the presence of considerable genetic heterogeneity from one tumor cell to another. It seems that a strong oncogenic stimulus overcomes the need for the acquisition and maintenance of numerous recurring chromosomal imbalances. We conclude that the sequential inactivation of multiple tumor suppressor genes, and the gain of function of several oncogenes by way of chromosomal abnormalities as seen in human breast carcinomas are reduced to the ampli®cation of HER2/neu and loss of mouse chromosome 4D. One could extend this observation to the hypothesis that mouse tumor models induced by tumor suppressor gene deletion more closely re¯ect the nature of multi-step carcinogenesis that we observe in human epithelial cancers. Induction of tumors by oncogene over-expression, however, provides an excellent tool for analysing the particular pathways in which these genes are involved.
Materials and methods

Tissue culture and metaphase chromosome preparation
Mammary epithelial cell lines were derived from primary tumors of 12 dierent MMTV-Cre Flox Neo NeuNT knockin mice (average latency 400 days). Tumor bearing animals (FVB 25%, CD1 25% and BALB/c 50%) were sacri®ced and cell lines prepared from tumor tissue as previously described (Amundadottir et al., 1995; McCormack et al., 1998) . Metaphase chromosomes were prepared following exposure to colcemid arrest (3 ± 4 h, ®nal concentration 100 mg/ml) and standard hypotonic treatment and ®xation in methanol/acetic acid.
Molecular cytogenetic analyses
Spectral karyotyping was performed as described (Liyanage et al., 1996) . Brie¯y,¯ow sorted normal mouse chromosomes were labeled with speci®c¯uorochromes or¯uorochrome combinations. After in situ hybridization images were acquired using an epi¯uorescence microscope (DMRXA, Leica, Wetzlar, Germany) connected to an imaging interferometer (SD200, Applied Spectral Imaging, Migdal HaEmek, Israel). Chromosomes were unambiguously identi®ed using a spectral classi®cation algorithm that results in the assignment of a separate classi®cation color to all pixels with identical spectra (Garini et al., 1996) . Chromosome aberrations were de®ned using the nomenclature rules from the International Committee on Standardized Genetic Nomenclature for Mice (Davisson, 1994) . Six to 10 metaphases were analysed for each tumor. For CGH, DNA was prepared using high salt extraction and phenol puri®cation and labeled by nick-translation using biotin-11-dUTP (Boehringer Mannheim, Indianapolis, IN, USA). Genomic DNA from strainmatched mice was prepared and labeled with digoxigenin-12-dUTP (Boehringer Mannheim). Hybridization was performed on karyotypically normal metaphase chromosomes (FVB strain) using an excess of mouse Cotl-DNA (Gibco-BRL, Gaithersburg, MD, USA). The biotin-labeled sequences were visualized with avidin-FITC (Vector Laboratories, Burlingame, CA, USA) and the digoxigenin labeled sequences were detected with a mouse derived antibody against digoxigenin followed by a secondary rhodamine conjugated anti mouse antibody (Sigma-Aldrich, Milwaukee, WI, USA). Quantitative¯uorescence imaging and CGH analysis was performed using Leica Q-CGH software (Leica Imaging Systems, Cambridge, UK). BAC clones (Research Genetics, Huntsville, AL, USA) containing locus speci®c sequences for the oncogenes HER2/neu and c-myc and the tumor suppressor genes BRCA1 and p53 and four BAC clones isolated from the RCPI23 genomic library containing the markers D4Mit149 (clone name 215G3), D4Mit254 (204N14), D4Mit229 (7J10), and 139P5 (speci®c for the p16 tumor suppressor gene) were used in this study. FISH probes were labeled with biotin or digoxigenin by nick translation and hybridized to chromosome preparations derived from the primary tumors. After over night hybridization at 378C, the slides were detected with FITC-conjugated avidin (Vector Laboratories, Burlingame, CA, USA) and TRITC-conjugated anti-digoxigenin antibodies, respectively (Sigma-Aldrich, St. Louis, MO, USA).
Immunohistochemistry
Cells were cultured on Falcon chamber slides (Thomas Scienti®c, Swedesboro, NJ, USA), washed in PBS, and ®xed with MetOH (08C) for 10 min and washed again in PBS. Incubation with a monoclonal anti g-tubulin antibody (Sigma, St. Louis, MO, USA) diluted 1 : 1000 in 3% goat serum/PBS was performed overnight at 378C. The antibody complexes were detected with TRITC-conjugated goat antirabbit IgG (Sigma, St. Louis, MO, USA) and counterstained with DAPI. When dual immuno¯uorescence experiments were performed, we used a polyclonal anti g-tubulin antibody (Sigma) and a monoclonal anti a-tubulin antibody (Sigma). Gray level images were acquired using a CCD camera (CH250, Photometrics, Tucson, AZ, USA) mounted on a Leica DMRBE epi¯uorescence microscope, and pseudocolored using Leica Q-Fish software. Further details for all Materials and methods can be found at http://www.riedlab.nci.nih.gov/.
